In the context of purinergic signaling, recent studies have shown that a single blockade of the A2A receptor, or in combination with PD-L1 or CTLA4 inhibitors, induces a defined T-cell activation, which limits tumor growth, leads to a Th1 gene expression signature consistent with immune activation and reinforces the memory immune cells [90]. Here, CTLA4 is linked to neoplasm.